Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-581 in Healthy Subjects and Cystic Fibrosis
NCT07283770Phase 1Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-581 in cystic fibrosis (CF) (7 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 105. Started Dec 2025; status: recruiting.
02
Drugs
VX-581
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07283770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283770.